These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 17235305)

  • 1. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
    Mahller YY; Vaikunth SS; Currier MA; Miller SJ; Ripberger MC; Hsu YH; Mehrian-Shai R; Collins MH; Crombleholme TM; Ratner N; Cripe TP
    Mol Ther; 2007 Feb; 15(2):279-86. PubMed ID: 17235305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
    Mahller YY; Rangwala F; Ratner N; Cripe TP
    Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
    Yamamura K; Kasuya H; Sahin TT; Tan G; Hotta Y; Tsurumaru N; Fukuda S; Kanda M; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Tanaka M; Kodera Y
    Ann Surg Oncol; 2014 Feb; 21(2):691-8. PubMed ID: 24170435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.
    Mahller YY; Vaikunth SS; Ripberger MC; Baird WH; Saeki Y; Cancelas JA; Crombleholme TM; Cripe TP
    Cancer Res; 2008 Feb; 68(4):1170-9. PubMed ID: 18281493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
    Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
    J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.
    Antoszczyk S; Spyra M; Mautner VF; Kurtz A; Stemmer-Rachamimov AO; Martuza RL; Rabkin SD
    Neuro Oncol; 2014 Aug; 16(8):1057-66. PubMed ID: 24470552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.
    Jackson JD; McMorris AM; Roth JC; Coleman JM; Whitley RJ; Gillespie GY; Carroll SL; Markert JM; Cassady KA
    Gene Ther; 2014 Nov; 21(11):984-90. PubMed ID: 25119379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
    Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
    Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
    Currier MA; Sprague L; Rizvi TA; Nartker B; Chen CY; Wang PY; Hutzen BJ; Franczek MR; Patel AV; Chaney KE; Streby KA; Ecsedy JA; Conner J; Ratner N; Cripe TP
    Oncotarget; 2017 Mar; 8(11):17412-17427. PubMed ID: 28147331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.
    Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL
    Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
    Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
    Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
    J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
    Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy.
    Kim Y; Saini U; Kim D; Hernandez-Aguirre I; Hedberg J; Martin A; Mo X; Cripe TP; Markert J; Cassady KA; Dhital R
    Front Immunol; 2024; 15():1375413. PubMed ID: 38895115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
    Holtkamp N; Malzer E; Zietsch J; Okuducu AF; Mucha J; Mawrin C; Mautner VF; Schildhaus HU; von Deimling A
    Neuro Oncol; 2008 Dec; 10(6):946-57. PubMed ID: 18650488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.